Post-esophagectomy hiatal hernia following minimally invasive esophagectomy in esophageal cancer patients.

Surg Endosc

Division of Gastrointestinal and General Surgery, Department of Surgery, Oregon Health & Science University, Portland, OR, 97239, USA.

Published: March 2025

Introduction: Minimally invasive esophagectomy (MIE) has emerged as the preferred surgical method for esophageal cancer resulting from lower morbidity rates for MIE compared to open surgery. However, post-esophagectomy hiatal hernia (PEHH), also known as paraconduit hernia, once rare, is now increasingly observed as a late complication. This study aims to ascertain the prevalence, predictive factors, and surgical management of PEHH following MIE in esophageal cancer patients.

Methods: We retrospectively reviewed esophageal cancer patients who underwent MIE between 2013 and 2023. Patients with PEHH were identified through clinical presentation and CT scans and compared to those without PEHH using statistical tests. Variables with p-values less than 0.2 were subjected to multivariate analysis.

Results: Among 371 patients, predominantly male with locally advanced disease (stages 2-4, 90.8%), 25 (6.7%) developed PEHH after a median interval of 24 months post-MIE. The PEHH group exhibited significantly lower BMI and shorter ICU stays. On multivariate analysis BMI < 25 kg/m2 (OR 2.96, CI 1.22-7.20, p = 0.02) and ICU stays (OR 0.67, CI 0.47-0.96, p = 0.03) were independent predictors of PEHH. Surgical repair was performed in 84% of PEHH cases, with 60% symptomatic and 48% emergency surgery. The minimally invasive approach was implemented in 15 patients (71.4%). Primary repair was successfully conducted in 14 cases (66.7%), while mesh was used in one-third of patients.

Conclusion: The increasing prevalence of PEHH with MIE warrants attention. A lower BMI and shorter ICU stay was associated with PEHH. Most cases are symptomatic and effectively managed through minimally invasive techniques.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00464-025-11639-yDOI Listing

Publication Analysis

Top Keywords

esophageal cancer
16
post-esophagectomy hiatal
8
hiatal hernia
8
minimally invasive
8
invasive esophagectomy
8
cancer patients
8
pehh
6
hernia minimally
4
esophageal
4
esophagectomy esophageal
4

Similar Publications

Backgrounds And Aims: Achalasia is an acquired esophageal neurodegenerative disorder, characterized by selective loss of inhibitory neurons in the myenteric plexus of the lower esophageal sphincter (LES). The Enteric neural precursor cell (ENPC) is essential in maintaining neurogenesis, but its role in achalasia pathogenesis is unknown. This study aimed to explore the neurogenesis status in the LES among achalasia patients.

View Article and Find Full Text PDF

Purpose: The aim of this study was to investigate the survival benefits of postoperative radiotherapy (PORT) in patients with resectable esophageal cancer (EC) after neoadjuvant therapy in the Immunotherapy era.

Methods: The study was designed as a retrospective cohort study, which included a total of 733 patients with EC from the SEER database and a single-center cohort. We used propensity score matching (PSM) to equilibrate patient characteristics.

View Article and Find Full Text PDF

Background: Esophageal squamous cell carcinoma (ESCC) represents a frequent cancer with a poor prognosis. Altered glucose metabolism contributes factor to ESCC progression. In our previous study, signal sequence receptor subunit delta (SSR4) was included in an ESCC prognostic model; however, the mechanisms underlying SSR4 implication in ESCC remain ambiguous.

View Article and Find Full Text PDF

In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy. This innovative approach involves engineering a patient's T cells to express receptors that specifically target tumor antigens, enhancing their ability to identify and eliminate cancer cells. However, the effectiveness of CAR-T therapy in solid tumors is often hampered by the challenging tumor microenvironment (TME).

View Article and Find Full Text PDF

Background: Immunotherapy has gained momentum with the discovery of novel antibodies targeting immunosuppressive proteins. HLA-E, a non-classical major histocompatibility complex class I (MHC-I) protein, exhibits immunosuppressive properties, potentially influencing tumor immune evasion mechanisms. The association between Human Leukocyte Antigen E (HLA-E) expression and outcomes in solid tumors remains unclear.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!